Robert H. Smith School of Business
The Motley Fool

Market Foolery Featured Podcasts

  • The Future of Starbucks is Hotdogs
    On today's show the guys take a look at earnings from eBay, Kinder Morgan, and Starbucks. Plus they discuss the latest industry that Google could disrupt.
  • Netflix is Taking Over the World
    On today's show the gang takes a look at earnings from Netflix and UnitedHealth Group. Plus they dive into the mailbag and discuss how to play the long term future of the energy industry. 
  • Coming Soon to a Theater Near You
    Amazon is getting into the movie business.  Halliburton’s 4th-quarter profits aren’t enough.  Plus we dip into the Fool Mailbag to discuss dividend-paying stocks.
Capital Business
Posted at 11:13 AM ET, 07/16/2012

GlaxoSmithKline buys Human Genome Sciences for $3.6B


Human Genome Sciences' headquarters in Rockville. (Jeffrey MacMillan - Capital Business)
British drugmaker GlaxoSmithKline has agreed to pay $3.6 billion for Rockville-based Human Genome Sciences after a months-long acquisition dispute over the company’s true value.

Glaxo has extended multiple buyout offers since April to both the HGS board of directors and its shareholders that valued the company at $2.6 billion, or $13 per share, but the company repeatedly rejected them as too low.

This latest agreement will fetch $14.25 per share in cash for HGS, a transaction value worth about $3.6 billion on an equity basis, or approximately $3 billion net of cash and debt, the companies said.

The deal brings an end to what had become an increasingly heated battle for control of the company.

Glaxo had attempted to bypass the board and purchase stock directly from investors. HGS then thwarted that effort with a poison pill, but gained a lawsuit from some disgruntled shareholders in response.

The two firms are development and marketing partners on several drugs, including Benlysta, which was approved by the Food and Drug Administration last year to treat systemic lupus.

By  |  11:13 AM ET, 07/16/2012

 
Read what others are saying
     

    © 2011 The Washington Post Company